 | Up a level |
2022
Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Font, E. F., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. (2021). CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation. J. Thorac. Oncol., 16 (1). S. S29 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
2020
Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. S. (2020). CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann. Oncol., 31. S. S894 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041